Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. [Review]
Citation: Circulation Research. 128(12):1973-1987, 2021 06 11.PMID: 34110908Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Agammaglobulinaemia Tyrosine Kinase/ai [Antagonists & Inhibitors] | *Antineoplastic Agents/ae [Adverse Effects] | *Cardiovascular Diseases/ci [Chemically Induced] | *Leukemia, B-Cell/dt [Drug Therapy] | *Protein Kinase Inhibitors/ae [Adverse Effects] | Antineoplastic Agents/tu [Therapeutic Use] | Arrhythmias, Cardiac/ci [Chemically Induced] | Atrial Fibrillation/ci [Chemically Induced] | Cancer Survivors | Hemorrhage/ci [Chemically Induced] | Humans | Hypertension/ci [Chemically Induced] | Molecular Targeted Therapy/ae [Adverse Effects] | Molecular Targeted Therapy/mt [Methods] | Protein Kinase Inhibitors/tu [Therapeutic Use] | Receptors, Vascular Endothelial Growth Factor/ai [Antagonists & Inhibitors]Year: 2021Local holdings: Available online from MWHC library: 1953 - presentISSN:- 0009-7330
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 34110908 | Available | 34110908 |
Available online from MWHC library: 1953 - present
Novel targeted cancer therapies have revolutionized oncology therapies, but these treatments can have cardiovascular complications, which include heterogeneous cardiac, metabolic, and vascular sequelae. Vascular side effects have emerged as important considerations in both cancer patients undergoing active treatment and cancer survivors. Here, we provide an overview of vascular effects of cancer therapies, focusing on small-molecule kinase inhibitors and specifically inhibitors of BTK (Bruton tyrosine kinase), which have revolutionized treatment and prognosis for B-cell malignancies. Cardiovascular side effects of BTK inhibitors include atrial fibrillation, increased risk of bleeding, and hypertension, with the former 2 especially providing a treatment challenge for the clinician. Cardiovascular complications of small-molecule kinase inhibitors can occur through either on-target (targeting intended target kinase) or off-target kinase inhibition. We will review these concepts and focus on the case of BTK inhibitors, highlight the emerging data suggesting an off-target effect that may provide insights into development of arrhythmias, specifically atrial fibrillation. We believe that cardiac and vascular sequelae of novel targeted cancer therapies can provide insights into human cardiovascular biology.
English